Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax Immunization to Assess Effects of MVA Vaccination on Dryvax Takes.

Next Previous
X
Search
Trial Profile

ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax Immunization to Assess Effects of MVA Vaccination on Dryvax Takes.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MVA 3000 (Primary) ; MVA 3000 (Primary) ; MVA 3000 (Primary) ; Modified vaccinia Ankara
  • Indications Smallpox
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 10 Mar 2010 Dryvax challenge results published in the Journal of Infectious Diseases.
    • 10 Mar 2010 Immunogenicity and reactogenicity results published in the Journal of Infectious Diseases.
    • 18 Sep 2008 Primary end point identified as safety as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top